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Abstract 
Background: Controlled human malaria infection (CHMI) by mosquito bite is a powerful tool for evaluation of vac‑
cines and drugs against Plasmodium falciparum malaria. However, only a small number of research centres have the 
facilities required to perform such studies. CHMI by needle and syringe could help to accelerate the development of 
anti‑malaria interventions by enabling centres worldwide to employ CHMI.
Methods: An open‑label CHMI study was performed with aseptic, purified, cryopreserved P. falciparum sporozoites 
(PfSPZ Challenge) in 36 malaria naïve volunteers. In part A, the effect of the inoculation volume was assessed: 18 
participants were injected intramuscularly (IM) with a dose of 2,500 PfSPZ divided into two injections of 10 µL (n = 6), 
50 µL (n = 6) or 250 µL (n = 6), respectively. In part B, the injection volume that resulted in highest infectivity rates 
in part A (10 µL) was used to formulate IM doses of 25,000 PfSPZ (n = 6) and 75,000 PfSPZ (n = 6) divided into two 
10‑µL injections. Results from a parallel trial led to the decision to add a positive control group (n = 6), each volunteer 
receiving 3,200 PfSPZ in a single 500‑µL injection by direct venous inoculation (DVI).
Results: Four/six participants in the 10‑µL group, 1/6 in the 50‑µL group and 2/6 in the 250‑µL group developed 
parasitaemia. Geometric mean (GM) pre‑patent periods were 13.9, 14.0 and 15.0 days, respectively. Six/six (100%) par‑
ticipants developed parasitaemia in the 25,000 and 75,000 PfSPZ IM and 3,200 PfSPZ DVI groups. GM pre‑patent peri‑
ods were 12.2, 11.4 and 11.4 days, respectively. Injection of PfSPZ Challenge was well tolerated and safe in all groups.
Conclusions: IM injection of 75,000 PfSPZ and DVI injection of 3,200 PfSPZ resulted in infection rates and pre‑patent 
periods comparable to the bite of five PfSPZ‑infected mosquitoes. Remarkably, it required 23.4‑fold more PfSPZ 
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administered IM than DVI to achieve the same parasite kinetics. These results allow for translation of CHMI from 
research to routine use, and inoculation of PfSPZ by IM and DVI regimens.
Trial registration: ClinicalTrials.gov NCT01771848.
Keywords: Controlled human malaria infection, Malaria, Plasmodium falciparum, Cryopreserved sporozoites, Human 
challenge infection
Background
Malaria is one of the oldest and deadliest foes of man-
kind. Transmission of this parasitic disease continues in 
97 countries worldwide, with 198 million cases of malaria 
and 584,000 deaths estimated in 2013, 90% of them 
occurring in Africa [1]. In the same year, malaria killed an 
estimated 437,000 African children under 5 years of age 
[1]. Moreover, malaria is an infectious disease not only 
endemic in poor countries but also an important contrib-
utor to the vicious cycle of poverty, having a significant 
negative impact on economic growth and development 
in these populations [2, 3]. Its eradication is currently 
on the global health agenda, an ambitious goal that will 
require the development, integration and implementa-
tion of more powerful strategies than the ones currently 
available, including new anti-malarial drugs and effective 
vaccines [4]. Nevertheless, as important as the new tools 
needed, are the methods to test them.
Controlled human malaria infection (CHMI) has 
facilitated progress in research and development of 
vaccines and drugs providing the possibility to infect 
volunteers under controlled conditions [5, 6]. Plasmo-
dium falciparum malaria is a pathogen particularly 
suited to challenge studies for several reasons: it has a 
relatively short incubation period, a standardized diag-
nostic laboratory test (thick smear microscopy) is avail-
able, strains known to be sensitive to all anti-malarial 
drugs can be used, and no known long-term sequelae 
or infectious state arise if properly treated [7]. First gen-
eration CHMI were performed with mosquitoes fed on 
the blood of volunteers who had been infected with P. 
falciparum by inoculation of blood-stage parasites [8]. 
After the development of in  vitro methods to culture 
P. falciparum, a second generation of CHMI was pos-
sible in which mosquitoes were fed upon gametocyte-
containing blood from cultures of well-characterized P. 
falciparum strains instead of infected human subjects 
[8, 9]. This second generation approach to CHMI, which 
was first reported in 1986 [9] has been iteratively stand-
ardized over the subsequent decades [8] and recently 
formally standardized under the umbrella of the World 
Health Organization (WHO) [10]. It generally involves 
the administration of P. falciparum sporozoites (PfSPZ) 
by the bites of five PfSPZ-infected Anopheles stephensi 
mosquitoes [8, 10], although exposure to the bites of 
three aseptically reared An. stephensi mosquitoes con-
sistently induces infection [11, 12]. Regardless, current 
methods of CHMI have facilitated substantial pro-
gress in the malaria research field by providing a safe 
and reproducible method to infect volunteers with P. 
falciparum.
CHMI by the bites of five mosquitoes consistently 
infects all malaria-naïve volunteers, with rare excep-
tions, with a geometric mean (GM) pre-patent period 
(time from exposure to PfSPZ to detection of parasites 
by microscopy) of less than 12 days (range 7.3–14.5) [6, 
8, 11, 13]. Mosquito bite CHMI, although being consid-
ered the more natural route of infection, has the limita-
tion of not allowing any calculation of the number of 
sporozoites (SPZ) inoculated per challenge, therefore 
leading to a large biological variability in the number 
of parasites injected per study participant. However, 
malaria research centres have achieved remarkable 
experience and standardization performing the sec-
ond generation of mosquito-administered CHMI since 
1986, with more than 1,500 volunteers challenged so 
far [8, 14, 15]. Nevertheless, these studies are complex 
in nature and as a result, can be performed only in a 
few research centres worldwide. With the increasing 
number of candidate vaccines and drugs in the research 
and development pipeline, it is necessary to increase 
accordingly the testing capacity and make CHMI stud-
ies broadly accessible, especially in malaria-endemic 
regions [7].
In the early 1950s, researchers at the National Insti-
tutes of Health, USA, were able to isolate Plasmodium 
malariae SPZ, preserve them at temperatures under 
−70°C for as long as 375  days and administer them to 
volunteers [16]. Infection rates obtained in trials per-
formed at that time were variable and SPZ preparations 
highly contaminated [17]. Currently however, it is possi-
ble to produce infectious, aseptic, purified, vialed, cryo-
preserved PfSPZ (PfSPZ Challenge) that can be injected 
by needle and syringe, a method that could represent 
the third generation of CHMI. Nevertheless, in order to 
provide an alternative to the standard mosquito-admin-
istered CHMI, PfSPZ Challenge will need to achieve the 
same results by consistently infecting 100% of volunteers 
with parasite kinetics similar to mosquito-administered 
infections.
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The present PfSPZ Challenge study was designed 
based on the results of trials conducted in Nijmegen 
(The Netherlands) [17], Oxford (UK) [7], and Tübingen 
(Germany) [18]. These three studies were designed to 
answer specific questions regarding the dose of cryo-
preserved PfSPZ, number of injection sites, and route of 
inoculation needed to achieve results similar to CHMI by 
mosquito bite regarding infectivity rate (100%) and GM 
pre-patent period (≤12 days). The first PfSPZ Challenge 
study performed in The Netherlands showed that injec-
tion of PfSPZ Challenge is infectious, safe and well tol-
erated [17]. This research group tested the intradermal 
(ID) route with doses of 2,500, 10,000 and 25,000 PfSPZ 
divided into two 50-µL injections. Infectivity rates and 
pre-patent periods obtained were not comparable to the 
bite of five infected mosquitoes. The second trial per-
formed in the UK achieved for the first time a 100% infec-
tivity rate with intramuscular (IM) injection of 25,000 
PfSPZ divided into two 50-µL injections, with a GM pre-
patent period of 12.7 days. The lack of dose response in 
this trial opened questions about other factors possibly 
affecting the efficacy of the inoculation. The third PfSPZ 
Challenge study performed in Germany tested for the 
first time the intravenous (IV) route in a dose escala-
tion trial, which assessed 50, 200, 800, and 3,200 PfSPZ 
administered [18]. As expected from the results in animal 
models [19], the IV route obtained optimal results with 
a dose of 3,200 PfSPZ in a single 500-µL injection by IV 
catheter, resulting in 100% infectivity rate and a GM pre-
patent period of 11.2 days. To complete the series of opti-
mization trials of PfSPZ Challenge, the objective of the 
present study was to assess at which dose and volume of 
injection does PfSPZ IM administration achieve infection 
kinetics equivalent to PfSPZ IV inoculation and five mos-
quito bites. Results of this study have major implications 
for future CHMI based in IM injection of PfSPZ.
Methods
Objectives
The primary objectives of the study were to assess in part 
A (1) the effect of changing the volume of IM injection; 
and, in part B (2) increasing the dose of PfSPZ by IM 
injection using the optimal volume determined in part A, 
on infectivity rates and pre-patent periods of PfSPZ Chal-
lenge. The secondary objective was to assess the safety 
of PfSPZ Challenge administered in various regimens. 
Additionally, this study aimed to verify the reproducibil-
ity of the results obtained in the PfSPZ Challenge study 
at the Institut für Tropenmedizin, Universität Tübingen 
(UKT) in Germany, that achieved 100% infectivity rate 
with a GM pre-patent period of 11.2  days (range 10.5–
12.5) in nine volunteers injected with a dose of 3,200 
PfSPZ in a volume of 500 µL by IV catheter.
Study design and participants
The study was an open-label, non-randomized, con-
trolled study in healthy adults conducted at the ISGlobal-
Barcelona Centre for International Health Research 
(CRESIB), Hospital Clínic-Universitat de Barcelona and 
at the Drug Research Centre (CIM), Institute of Biomedi-
cal Research (IIB), Research Institute of Santa Creu and 
Sant Pau Hospital, Barcelona, Spain from December 2012 
to July 2013. Volunteers 18–45 years of age were invited 
to participate and screened for eligibility. The main target 
group for recruitment was students from the Universitat 
de Barcelona (UB) and their close relatives and friends. 
Two information sessions (~150 students attended in 
total) were held at the UB School of Medicine to explain 
the study and invite subjects to participate. Subsequently, 
interested students (groups of 4–14) were interviewed 
by the study physicians to provide more detailed infor-
mation and answer questions. Additionally, institutional 
emails (ISGlobal, CRESIB, Hospital Clínic) were sent 
informing and inviting participation in the study. Eligi-
bility was assessed by medical history, physical exami-
nation, standard haematological and biochemical tests, 
measurement of antibodies to asexual, erythrocytic P. fal-
ciparum parasites by indirect immunofluorescence test 
[IIFT, EUROINMUNO  Medizinische Labordiagnostika 
AG; EUROPLUS: Plasmodium falciparum/Plasmodium 
vivax (IgG-IgM)], human immunodeficiency virus (HIV), 
hepatitis B, and hepatitis C serology, urine pregnancy 
test, electrocardiogram and risk assessment of cardiovas-
cular disease. Main exclusion criteria were residence in 
a malaria-endemic region within the previous 6 months, 
history of receiving an investigational malaria vaccine, 
positive P. falciparum serology, pregnancy, any finding 
that suggested a chronic condition, or that in the opin-
ion of the study physician, could significantly increase 
the risk to the volunteer of developing severe malaria 
infection.
Before any intervention (medical history, screening 
tests) all volunteers gave written informed consent and 
answered correctly a questionnaire aimed to test their 
understanding of the study. They were requested to give 
three close contact phone numbers and social security 
numbers, to be able to search for them in case of miss-
ing follow-up visits. The study received approval by the 
ethics committees of Hospital Clínic and Hospital de 
la Santa Creu i Sant Pau together with the administra-
tive clearance provided by the Health Department of 
Generalitat de Catalunya. The study followed the prin-
ciples of the Declaration of Helsinki in its 6th revision 
(2008) as well as International Conference on Harmoni-
zation—Good Clinical Practice (ICH-GCP) guidelines. 
The study is registered with ClinicalTrials.gov number 
NCT01771848.
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PfSPZ challenge product
SPZ from P. falciparum strain NF54 fully susceptible to 
chloroquine were purified, and cryopreserved at a speci-
fied concentration at Sanaria Inc. facilities as described 
[7, 15, 17, 20]. PfSPZ Challenge is dispensed into screw-
cap vials containing 15,000, 50,000 or 100,000 PfSPZ 
in 20-µL aliquots and stored in liquid nitrogen vapour 
phase at −140 to −196°C [20]. Two separate lots of 
PfSPZ were used in the Barcelona trial: one lot for part 
A and a second lot for part B, produced in March 2011 
and July 2012, respectively. PfSPZ Challenge released for 
clinical use meets quality control specifications includ-
ing sterility, purity and potency [20, 21]. The quality con-
trol release and stability programme assessed potency 
and viability using in vitro infection of cultured human 
hepatocytes (HC-04) and a membrane integrity assay 
(see Additional file 1: Table S1), respectively [17, 20, 21]. 
Briefly, 50,000 PfSPZ were added to 40,000 HC-04 (1F9) 
cells and cultured for 6  days. Late liver stage parasites 
were detected by staining with a monoclonal antibody 
against P. falciparum merozoite protein 1. Membrane 
integrity was tested by fluorescence microscopy of PfSPZ 
following incubation with SYBR green and propidium 
iodide. Volunteers were inoculated within 30  min after 
thawing of PfSPZ.
Inoculation of PfSPZ challenge
Volunteers were assigned to six different groups (Group 
1–6). Three groups were inoculated in part A and three 
in part B, according to the order of enrolment. Addition-
ally, back-up volunteers were screened and inoculated 
only if any of the initially assigned volunteers withdrew or 
did not fulfill the study criteria shortly before the inocu-
lation date (Fig.  1). The inoculation of PfSPZ Challenge 
took place in January 2013 (part A) and April 2013 (part 
B) at the Drug Research Centre (CIM), Research Institute 
of Santa Creu and Sant Pau Hospital, Barcelona. In part 
A, 18 volunteers received a dose of 2,500 PfSPZ divided 
in two IM injections (1,250 PfSPZ per injection) in three 
different volume suspensions: Group 1, 10  µL (n  =  6), 
Group 2, 50 µL (n = 6) and Group 3, 250 µL (n = 6), one 
injection in each deltoid. In part B, the optimal injection 
volume determined in part A (10  µL) was used for IM 
injection of higher doses. Group 5 received 25,000 PfSPZ 
(n = 6) divided in two separated doses of 12,500 PfSPZ in 
10 µL; and Group 6 received 75,000 PfSPZ (n = 6) divided 
in two separated doses of 37,500 PfSPZ in 10 µL, respec-
tively injected in the deltoid (IM) of each arm. In a third 
group, Group 4 (n = 6), 3,200 PfSPZ suspended in 500 μL 
were administered by direct venous inoculation (DVI) 
into the right arm immediately after venipuncture using a 
Part A
Assessed for eligibility
n = 35
0
2500 PfSPZ IM in 50 μL
n = 6
2500 PfSPZ IM in 250 μL
n = 6
Eligible and 
inoculated n = 18
Back up 
inoculated n = 3 
(out of 3)
Part B
Assessed for eligibility
n = 36
1
23
25,000 PfSPZ IM in 10 
μL n = 6
Eligible and 
inoculated n = 18
Back up 
inoculated n = 3 
(out of 6)
75,000 PfSPZ IM in 10 
μL n = 6
3,200 PfSPZ DVI in 500 
μL (verification group)
4
Part A Optimal 
volume of 
inoculation = 10
μL
2500 PfSPZ IM in 10 μL
n = 6
Excluded
Consent withdraw n = 5
Screening Failure n = 12 
Excluded
Consent withdraw n = 6
Screening Failure n= 9
Preliminary analysis
Fig. 1 Flow chart of volunteer recruitment. This trial was divided in two parts. In part A the impact of volume of inoculation on infectivity rate 
and pre‑patent period was tested by injecting the same dose of P. falciparum sporozoites (PfSPZ) in three different injection volumes. In part B, 
the volume that resulted in the highest infectivity rate was used for the formulation of two increased IM doses. A DVI group was included in part 
B to independently corroborate the results of the trial in Tübingen [18]. IM intramuscular, DVI direct venous inoculation, back up refers to the extra 
volunteers who were enrolled in each part of the study. Group 1: 2,500 PfSPZ in 10 μL; group 2: 2,500 PfSPZ in 50 μL; group 3: 2,500 PfSPZ in 250 μL; 
group 4: 3,200 PfSPZ in 500 μL; group 5: 25,000 PfSPZ in 10 μL; group 6: 75,000 PfSPZ in 10 μL.
Page 5 of 13Gómez‑Pérez et al. Malar J  (2015) 14:306 
1 mL syringe with a 25G × 16 mm needle. An IV catheter 
was inserted in the left arm prior to PfSPZ DVI to serve as 
emergency access in case of anaphylactic reaction.
Procedures
All volunteers were observed for at least 1 h after PfSPZ 
Challenge administration (Day 0) and examined on the 
following day (Day 1). Participants were provided with 
a diary where they were instructed to register their daily 
symptoms and concomitant medication taken, as well as 
with a card with contact information (telephone numbers 
of study physicians) and a digital thermometer. Between 
Day 2 and Day 5 volunteers were contacted daily by tel-
ephone. In part A, twice-daily visits and thick blood 
smears (TBS) were performed from Day 6 until the first 
positive blood smear or Day 21 was reached. In part B, 
once-daily visits were performed between Days 6 and 9, 
followed by twice-daily visits from Day 10 onwards. TBS 
were performed with blood samples taken by venipunc-
ture in 2-mL EDTA tubes. On the day of first parasite 
detection by microscopy or Day 21, volunteers started a 
curative anti-malarial treatment with chloroquine. When 
chloroquine was contra-indicated as in the case of two 
volunteers with psoriasis, participants were treated with 
atovaquone–proguanil. Later follow-up visits of volun-
teers were performed on Days 35 and 90 after inocula-
tion. Every time blood was taken for TBS, an extra blood 
sample was drawn in a 2-mL EDTA tube and stored at 
−80°C for subsequent assessment of sub-microscopic 
parasitaemia by quantitative real time polymerase reac-
tion (qPCR). qPCR was performed retrospectively once 
all follow-up visits were completed. Adverse events (AE) 
and clinical symptoms were reviewed daily and graded 
according to standard criteria of the US Food and Drug 
Administration (FDA) guidelines [22] until day of treat-
ment completion and at all follow-up visits thereafter.
Laboratory method of diagnosis
Successful infection was defined as the appearance of 
asexual parasites in peripheral blood, detected by TBS 
microscopy. The pre-patent period was defined as the 
time between PfSPZ Challenge injection and first positive 
TBS. Quantitative TBS were prepared as described else-
where [23]. In brief, 10 μL of blood were spread evenly 
on a 1 × 2 cm area of a slide, dried in an incubator and 
stained with Giemsa. Four smears were prepared at each 
visit. At least two microscopists were required to observe 
a minimum of two unambiguous parasites in independent 
readings to declare a slide positive. For each time point 
the reader performed five passes in one of the four smears 
(five passes equivalent to assessing 0.5 μL of blood, with 
some variations depending on the characteristics of 
the microscope objective lens) when the volunteer was 
considered asymptomatic by the clinician of the study, 
and 24 passes when the participant was considered symp-
tomatic. Limit of detection of TBS when reading five 
passes was ~four parasites per μL. Reading more than five 
passes improves the detection capacity of the TBS detect-
ing smaller parasite densities. Parasitaemia was estimated 
by qPCR by methods previously described [24] and per-
formed at the UKT in Germany. Limit of quantification of 
qPCR was 30 parasites per mL.
Statistical analysis
Data were double-entered using the OpenClinica™ [25] 
software for clinical data management. The main analy-
sis was done on the intention to treat (ITT) cohort that 
included all volunteers who underwent CHMI with PfSPZ 
Challenge. AEs were analysed as pre-erythrocytic phase 
adverse events or erythrocytic phase adverse events as 
specified in the correspondent section below. AEs were 
categorized as related to PfSPZ inoculation, malaria and 
anti-malarial treatment. The pre-patent period was calcu-
lated in days dividing by 24 the number of hours from time 
of inoculation until time of first positive TBS and sum-
marized by group using geometric means. Times to first 
positive TBS were visualized using Kaplan–Meier graphs 
(Fig.  2). All calculations were done with Stata statistical 
software version 14. Graphs of parasite density by qPCR 
were done with R version 3.1.0. Graphs of pre-patent peri-
ods by groups were done with GraphPad Prism 5.01.
Fig. 2 Kaplan–Meier plot of time to infection. OM optic micros‑
copy; group 1: 2,500 PfSPZ in 10 μL × 2 IM; group 2: 2,500 PfSPZ in 
50 μL × 2 IM. Group 3: 2,500 PfSPZ in 250 μL × 2 IM; group 4: 3,200 
PfSPZ in 500 μL × 1 DVI; group 5: 25,000 PfSPZ in 10 μL × 2 IM; 
group 6: 75,000 PfSPZ in 10 μL × 2 IM; PfSPZ P. falciparum sporozoites, 
IM intramuscular injection, DVI direct venous inoculation.
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Results
Safety
Eligibility criteria was assessed in 71 volunteers from 
which 36 were enrolled (Fig.  1). Twenty-five of the 36 
participants developed P. falciparum parasitaemia and all 
had mild malaria. No volunteer required hospitalization, 
and all were successfully cured by anti-malarial treat-
ment, no serious AE (SAE) occurred. Twenty-three of the 
participants who developed malaria had a negative TBS 
1  day after onset of treatment. The two volunteers who 
were still positive by TBS 1 day after onset of treatment 
became TBS negative 2 days after diagnosis.
Pre‑erythrocytic phase adverse events
The pre-erythrocytic phase was considered the period 
between injection of PfSPZ Challenge inoculation and 
Day 5 after injection. Mild local reactogenicity to PfSPZ 
Challenge was present in one volunteer from Group 
3 (2,500 PfSPZ IM in 250  µL) and one volunteer from 
Group 2 (2,500 PfSPZ IM in 50 µL). The latter scratched 
the site of injection immediately after the inoculation 
took place and who had a non-pruritic, painless 4-mm 
diameter erythematous and edematous area at one of the 
injection sites that lasted 1  day. This volunteer did not 
develop parasitaemia. All AEs observed during the pre-
erythrocytic phase were transient and the majority were 
mild (Tables  1, 2). Only two volunteers had headaches, 
which were of moderate intensity during this period that 
responded favourably to acetaminophen treatment and 
lasted a few days. No severe AEs (Grade 3) were observed 
during the pre-erythrocytic phase and there were no dif-
ferences in the frequency of AEs between the groups. No 
SAE occurred.
Erythrocytic phase adverse events
The analysis of the AEs observed during erythrocytic rep-
lication was divided into two phases: (1) after day 5 (D5) 
and before malaria diagnosis or D21 for those who did 
Table 1 Number of  AEs or laboratory abnormalities by  grade and  group in  the pre-erythrocytic phase: between  day 
of injection (day 0) and day 5
No grade 3 adverse events were registered during this period.
PfSPZ Plasmodium falciparum sporozoite, IM intramuscular injection, DVI direct venous inoculation.
Severity grade Challenge group (n = 6 per group) Total
Group 1
2,500 PfSPZ 
10 µL × 2 IM
Group 2
2,500 PfSPZ 
50 µL × 2 IM
Group 3
2,500 PfSPZ 
250 µL × 2 IM
Group 4
3,200 PfSPZ 
500 µL × 1 DVI
Group 5
25,000 PfSPZ 
10 µL × 2 IM
Group 6
75,000 PfSPZ 
10 µL × 2 IM
Grade 1 2 7 5 7 6 2 29
Grade 2 4 1 1 1 2 2 11
Total 6 8 6 8 8 4 40
Table 2 Type and  number of  grade 2 adverse events in  the pre-erythrocytic phase: between  day of  injection (day 0) 
and day 5
PfSPZ Plasmodium falciparum sporozoite, IM intramuscular injection, DVI direct venous inoculation.
Adverse event 
description
CHMI Groups Total
Group 1
2,500 PfSPZ 
10 µL × 2 IM
Group 2
2,500 PfSPZ 
50 µL × 2 IM
Group 3
2,500 PfSPZ 
250 µL × 2 IM
Group 4
3,200 PfSPZ 
500 µL × 1 DVI
Group 5
25,000 PfSPZ 
10 µL × 2 IM
Group 6
75,000 PfSPZ 
10 µL × 2 IM
Abdominal pain 1 0 0 0 0 0 1
Atopic dermatitis 
lesions
0 1 0 0 0 0 1
Common cold 0 0 0 0 0 1 1
Diarrhoea 0 0 1 0 0 0 1
Dysmenorrhoea 0 0 0 1 1 1 3
Dyspepsia 1 0 0 0 0 0 1
Headache 1 0 0 0 1 0 2
Muscle spasm 1 0 0 0 0 0 1
Total 4 1 1 1 2 2 11
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not develop parasitaemia; and, (2) after treatment, which 
was on the day of diagnosis for those who developed 
parasitaemia and on D21 for those who did not develop 
parasitaemia, through to the completion of follow-up vis-
its on D90.
No Grade 3 AEs were observed during the first eryth-
rocytic phase after D5 and before diagnosis of malaria 
or D21. The most frequent Grade 2 AE attributed to 
malaria during this phase was headache (27%), followed 
by fatigue (7%). Only one volunteer developed a Grade 
2 fever (38°C); this occurred one visit before malaria 
diagnosis. A detailed list of the AEs of moderate inten-
sity (Grade 2) observed during this period is provided in 
Additional file 2: Table S2.
A total of 377 AEs occurred after the day of malaria 
diagnosis or D21 and the completion of the follow-up 
visits (Table  3). The vast majority were mild (Grade 1; 
n  =  235). In addition, 117 moderate (Grade 2) and 25 
severe (Grade 3) AEs were observed. The most com-
mon Grade 2 AE was again headache (14.5%) follow by 
fever (9.4%), malaise (6%) and myalgia (5%) (see Addi-
tional file 3: Table S3). Two participants presented fever 
of Grade 2 in between the twice-daily scheduled visits; 
they were requested to come to the clinic and malaria 
was diagnosed by TBS. Most of the time symptoms pre-
sented together, especially fever and headache. All symp-
toms were well controlled with acetaminophen. Two 
volunteers had moderate anaemia 2 days after initiation 
of malaria treatment, one with haemoglobin of 10.3  g/
dL (baseline value 12  g/dL), and the other one with a 
haematocrit of 32% (baseline value 36%) that persisted 
until Day 35 (D35) after PfSPZ Challenge inoculation. 
Iron supplementation was initiated and haemoglobin and 
haematocrit values normalized until the last follow-up 
visit 90 days after PfSPZ Challenge (D90). One volunteer, 
who had normal values of haemoglobin and haemato-
crit following malaria treatment and at the D35 visit, had 
moderate anaemia at D90. The volunteer was referred to 
the tropical medicine department of the Hospital Clínic 
for further studies. Several participants had transient 
laboratory abnormalities expected during malaria infec-
tions (Table 4). The most common Grade 3 AE was lym-
phopaenia (32%) followed by fever (28%) and decreased 
neutrophil count (12%) (see Additional file 4: Table S4). 
Severe AEs were transient and at frequencies expected 
following P. falciparum infection. No SAE occurred. A 
summary of the frequency of volunteers that presented 
Grade 3 AEs in both pre-erythrocytic and erythrocytic 
stages by inoculation group is shown in Additional file 5: 
Table S5.
Two volunteers presented during clinical malaria 
with additional symptoms. One 40-years old female, 
who received 3,200 PfSPZ by DVI, was diagnosed with 
malaria with a parasitaemia of 1.25 parasites/µL 10 days 
after inoculation of PfSPZ Challenge. She received chlo-
roquine treatment immediately after, with malaria symp-
toms lasting 24  h and with a negative TBS 1  day after 
onset of treatment. Between the third and the fourth 
dose of chloroquine, (24 and 48  h after the first dose, 
respectively), she developed anxiety, insomnia, anhe-
donia and anticipatory fear. As malaria symptoms were 
absent and the TBS was negative; she was referred to the 
psychiatry department of the Hospital Clínic where she 
was diagnosed with unspecified anxiety disorder. She 
received benzodiazepines for 2  months and was safely 
managed as an outpatient. No anxiety was reported at 
D90 visit. Another female volunteer, a 20-years old, UB 
medical student, who received 75,000 PfSPZ IM, was 
diagnosed with malaria with a parasitaemia of 3.3 para-
sites/µL 12 days after injection of PfSPZ Challenge. She 
Table 3 Number of  AEs or laboratory abnormalities by  grade and  group in  the erythrocytic phase: after  initiation 
of treatment of malaria or day 21 until the end of follow up visits on day 90
PfSPZ Plasmodium falciparum sporozoite, IM intramuscular injection, DVI direct venous inoculation.
Severity grade Challenge group Total
(n = 6 for each group)
Group 1
2,500 PfSPZ 
10 µL × 2 IM
Group 2
2,500 PfSPZ 
50 µL × 2 IM
Group 3
2,500 PfSPZ 
250 µL × 2 IM
Group 4
3,200 PfSPZ 
500 µL × 1 DVI
Group 5
25,000 PfSPZ 
10 µL × 2 IM
Group 6
75,000 PfSPZ 
10 µL × 2 IM
No subjects with P. 
falciparum parasi‑
taemia
4 1 2 6 6 6 25
Grade 1 25 21 23 51 53 62 235
Grade 2 18 8 18 28 19 26 117
Grade 3 2 0 4 6 4 9 25
Total 45 29 45 85 76 97 377
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presented after the second dose of chloroquine (6 h after 
onset of treatment) with parasternal chest pain of mod-
erate intensity, described as a burning sensation, accom-
panied by shortness of breath after moderate effort. Due 
to the antecedent of a cardiac AE after initiation of treat-
ment for malaria in a CHMI in The Netherlands [26], 
she was evaluated in the emergency room of the Hos-
pital Clínic shortly after the onset of symptoms. Oxy-
gen saturation was 98% on room air, electrocardiogram 
(EKG) showed non-specific changes, and haematological 
and biochemical tests, including cardiac enzymes, were 
normal, except for D-dimer that was increased with a 
value of >10,000 ng/mL (normal <500 ng/mL). Increased 
plasma concentrations of D-dimer have been reported 
during malaria infections [27], thus once a cardiac event 
was ruled out, painkillers were administered. The symp-
toms rapidly and significantly diminished and the vol-
unteer was discharged a few hours later. The following 
day, symptoms were milder and EKG and CT-pulmo-
nary angiogram were normal. Follow-up EKG and car-
diac enzymes were normal during the subsequent 72  h, 
although she continued to have shortness of breath after 
moderate exertion. Seven days after the event, a cardiac 
MRI and haematological and biochemistry tests were 
normal, including D-dimer values, and she was asymp-
tomatic. During the following visits, the volunteer was 
asymptomatic with no abnormalities in blood tests. Nei-
ther of these two volunteers had history of similar events, 
and both denied illegal drug consumption.
Infectivity of PfSPZ challenge
Thirty-six healthy volunteers, 20 women and 16 men 
between ages 19 and 41, were enrolled out of a group 
of 71 volunteers who were assessed for eligibility (Fig. 1; 
Table 5). Demographic characteristics were similar in all 
groups (Table 5). TBS diagnosis was made promptly, with 
parasite densities ranging from 0.83 to 56 parasites/µL. 
In part A, 4/6, 1/6 and 2/6 volunteers developed parasi-
taemia in the 10, 50 and 250 µL groups, respectively. GM 
pre-patent periods were 13.9, 14.0 and 15  days, respec-
tively. Since the infection rate was highest in the 10-µL 
inoculum group, IM dose escalation was done using 
10-µL injections.
In part B, 18/18 (100%) volunteers developed parasitae-
mia. GM pre-patent periods were 11.4, 12.2 and 11.4 days 
for Group 4 (3,200 PfSPZ DVI), Group 5 (25,000 PfSPZ 
IM) and Group 6 (75,000 PfSPZ IM), respectively (Fig. 2; 
Table  6). There is a significant difference between the 
pre-patent periods of Group 4 and Group 5 (Kruskal–
Wallis test, p = 0.0374), while there is not a statistically 
significant difference between Group 4 and Group 6 pre-
patent periods (Kruskal–Wallis test, p = 1.0000).
As the PfSPZ dose was increased from 2,500 to 25,000 
to 75,000 PfSPZ in a constant 10-μL volume admin-
istered IM, the pre-patent period decreased: Group 
1 (2,500 PfSPZ in 10  µL IM) had an infectivity rate of 
67% and a GM pre-patent period of 13.9  days; Group 
5 (25,000 PfSPZ in 10  µL IM) had an infectivity rate 
of 100% and a GM pre-patent period of 12.2  days; and 
Table 4 Number of  volunteers with  haematological and  biochemical changes at  24  h after  initiation of  treatment 
for Plasmodium falciparum infection and on days 35 and 90 after injection of PfSPZ Challenge
HB haemoglobin, WBC white blood cells, ALT alanine aminotransferase, AST aspartate transaminase, LDH lactate dehydrogenase.
Parameter Normal range Ranges of labora‑
tory abnormalities
Number of volunteers with laboratory abnormalities among the  
25 that developed malaria
Screening 24 h after first 
detection of  
parasitaemia
Day 35 after injec‑
tion of PfSPZ  
Challenge
Day 90 after injec‑
tion of PfSPZ 
Challenge
Hb level 120–170 g/L <120 g/L 1 (119 g/L) 5 (lowest value 
106 g/L)
5 (lowest value 
103 g/L)
3 (lowest value 
104 g/L)
WBC count 4.0–11.0 × 109 cells/L <4.0 × 109 cells/L 2 (lowest value 
3.75 × 109 cells/L)
16 (lowest value 
2.4 × 109 cells/L)
1 (3.6 × 109 cells/L) 0
Lymphocyte 
count
0.9–4.5 × 109 cells/L <0.9 × 109 cells/L 0 16 (lowest value 
0.3 × 109 cells/L)
0 0
Platelet count 130–400 × 109 cells/L <130 × 109 cells/L 0 6 (lowest value 
68 × 109 cells/L)
0 0
ALT 5–40 IU/L ≥1.1 ULN 0 6 (highest value 
159 IU/L)
0 0
AST 5−40 IU/L ≥1.1 ULN 1 (58 IU/L) 6 (highest value 
125 IU/L)
0 1 (44 IU/L)
LDH <450 IU/L ≥450 IU/L 2 (highest value 
515 IU/L)
9 (highest value 
652 IU/L)
1 (466 IU/L) 0
Creatinine 0.3–1.3 mg/dL Any abnormality 0 0 0 0
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Group 6 (75,000 PfSPZ in 10 µL IM) had an infectivity 
rate of 100% and a GM pre-patent period of 11.4  days. 
Pre-patent periods compared between these three 
groups were significantly different (Kruskal–Wallis test, 
p = 0.0080) which was attributed to the reduction in the 
pre-patent period in the 75,000 PfSPZ dose group com-
pared to that in the 2,500-dose group (Mann–Whitney 
test, p = 0.0105) or the 25,000-dose group (Mann–Whit-
ney test, p = 0.0250) (Fig. 3). Additional file 6: Figure S1 
shows parasite density by qPCR from Groups 1, 5 and 6 
to visualize the changes in parasite kinetics as the PfSPZ 
dose increases.
The results of the UKT trial using IV injection were 
successfully replicated using DVI. In the present study, 
volunteers in the 3,200 PfSPZ Challenge DVI group 
received a different lot than in the UKT trial of PfSPZ 
Challenge administered by a different research team 
with a 100% infectivity rate and a GM pre-patent period 
of 11.4 days. Comparable results were obtained with the 
75,000 PfSPZ Challenge IM group in which all volunteers 
Table 5 Demographic characteristics of the participants
kg kilogram, m meter, BMI body mass index, Min minimum value of the range, Max maximum value of the range.
Variable Group 1
2,500 PfSPZ 
in 10 µL IM
N = 6
Median
(Min; max)
Group 2
2,500 PfSPZ 
in 50 µL IM
N = 6
Median
(Min; max)
Group 3
2,500 PfSPZ 
in 250 µL IM
N = 6
Median
(Min; max)
Group 4
3,200 PfSPZ 
in 500 µL DVI
N = 6
Median
(Min; max)
Group 5
25,000 PfSPZ 
in 10 µL IM
N = 6
Median
(Min; max)
Group 6
75,000 PfSPZ 
in 10 µL IM
N = 6
Median
(Min; max)
Total
N = 36
Median
(Min; max)
Age (years) 33 26 30 29 22 25 26
(21; 41) (21; 32) (24; 35) (19; 40) (20; 25) (20; 32) (19; 41)
Weight (Kg) 63 67 80 61 60 54 63
(58; 86) (51; 79) (58; 93) (54; 73) (51; 70) (52; 79) (51; 93)
Height (m) 1.71 1.71 1.74 1.69 1.7 1.64 1.7
(1.68; 1.75) (1.65; 1.86) (1.63; 1.85) (1.59; 1.72) (1.56; 1.75) (1.60; 1.84) (1.56; 1.86)
BMI (kg/m2) 22 21.5 26.2 22.8 21.3 20.3 22
(20.1; 28.1) (18.0; 25.8) (21.9; 30.7) (19.1; 24.8) (19.9; 22.8) (19.4; 23.5) (18.0; 30.7)
Sex
 Female 2 (33%) 3 (50%) 1 (17%) 4 (67%) 5 (83%) 5 (83%) 20 (56%)
 Male 4 (67%) 3 (50%) 5 (83%) 2 (33%) 1 (17%) 1 (17%) 16 (44%)
Table 6 Parasitaemia data by microscopy and qPCR and pre-patent periods by group
Group 1 Group 2 Group 3 Group 4 Group 5 Group 6
2,500 PfSPZ 
10 µL × 2 IM
2,500 PfSPZ 
50 µL × 2 IM
2,500 PfSPZ 
250 µL × 2 IM
3,200 PfSPZ 
500 µL × 1 DVI
25,000 PfSPZ 
10 µL × 2 IM
75,000 PfSPZ 
10 µL × 2 IM
N = 6 N = 6 N = 6 N = 6 N = 6 N = 6
Number of volunteers who became 
thick blood smear positive (TBS+)
4 1 2 6 6 6
Listing of times to TBS+ (days) 14.0, 15.0, 15.0, 
12.0
14.0 16.0, 14.0 11.0, 10.4, 12.3, 
10.9, 11.9, 12.2
12.4, 12.4, 13.3, 
12.4, 11.1, 
12.0
11.8, 11.0, 11.0, 11.0, 
12.0, 12.0
Geometric mean time to TBS+ (days) 13.9 14.0 15.0 11.4 12.2 11.4
Listing of parasite density at time of 
TBS+ (parasites/µL blood)
10.0, 48.0, 6.0, 5.0 34.0 10.0, 27.0 5.0, 1.3, 10.0, 8.0, 
12.0, 14.0
4.0, 10.0, 5.8, 
10.0, 3.8, 3.3
56.0, 0.8, 0.8, 6.0, 
3.3, 6.6
Geometric mean parasite density at 
time of TBS+ (parasites/µL blood)
11.0 34.0 16.4 6.6 5.5 4.1
Listing of times to qPCR+ (days) 11.0, 11.3, 11.4, 
10.0
9.1 11.0, 8.0 6.9, 9.1, 8.0, 8.0, 
9.0, 8.9
10.1, 8.0
9.1, 7.0
7.0, 7.1
6.9, 7.0, 7.0, 7.0
7.0, 6.0
Geometric mean of time to 
qPCR+ (days)
10.9 9.1 9.3 8.3 7.9 6.8
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were infected with a GM pre-patent period of 11.4 days. 
All volunteers receiving 25,000 PfSPZ IM were infected 
but the GM pre-patent period was extended to 12.2 days.
Parasite kinetics measured by qPCR
All positive TBS results were confirmed by qPCR except 
for the results of one volunteer from part A who received 
2,500 PfSPZ IM in two 250-µL injections. The TBS from 
this volunteer was read again by two microscopists after 
the qPCR results and no parasites were found, thus con-
firming the false positive TBS result. The pre-patent 
period of this volunteer was not included in the analysis 
of the GM pre-patent period of the corresponding group, 
and this result did not affect the outcome of the prelimi-
nary analysis in part A regarding the optimum volume 
of inoculation. None of the TBS negative volunteers 
reached qPCR positivity threshold. Figure  4 and Addi-
tional file 7: Figure S2 (in colours) plots the qPCR results 
per group of inoculation. On average, qPCR detected 
parasites 4.0 days (range 1.4–6.0) before microscopy (see 
Additional file 8: Table S6).
Discussion
PfSPZ Challenge administered by IM and DVI injec-
tion is safe and well tolerated. The clinical observa-
tions here described are in agreement with previously 
reported clinical data from both mosquito- and needle 
and syringe-administered CHMI trials [7, 8, 13, 17, 28]. 
Most of the AEs (51%) were attributed (possibly, prob-
ably or definitely related) to malaria and few to PfSPZ 
inoculation (2%). TBS diagnosis was made promptly and 
volunteers were treated immediately. All participants 
responded favourably to a curative dose of chloroquine or 
atovaquone–proguanil. Both drugs were effective. Never-
theless, there were two clinical cases that caused concern. 
One subject developed significant anxiety and another 
non-cardiac, parasternal chest pain and excertional dysp-
nea after initiation of chloroquine treatment for P. falci-
parum parasitaemia. Review of the screening procedures 
and the clinical history of the volunteers indicated that 
there was nothing that would have suggested that these 
two volunteers were at increased risk for a reaction to 
treatment of malaria with chloroquine. However, the 
volunteer with anxiety and her family indicated she had 
a tendency to be anxious. Nonetheless, it is considered 
possible that chloroquine treatment was the cause of the 
anxiety symptoms described above, since such AEs have 
been reported in relation to this anti-malarial drug [29]. 
There is not certainty about what caused the non-cardiac 
parasternal chest pain and exertional dyspnoea. Malaria 
is sometimes associated with chest pain, and it has been 
reported that severe malaria with high parasitaemia, 
which this subject did not have, can mimic acute myocar-
dial infarction [30].
First it was assessed whether increasing the volume of 
inoculation of 2,500 PfSPZ IM from 10 to 50 to 250  µL 
changed the infectivity rate and/or pre-patent period. The 
sample was small and the differences between groups not 
significant, but among the volunteers receiving 2,500 PfSPZ, 
the highest infection rate (4/6) and the shortest pre-patent 
period (13.9  days) occurred in those volunteers adminis-
tered 2,500 PfSPZ in 10 μL. As the dose was increased from 
2,500 to 25,000 to 75,000 PfSPZ in a constant 10-μL volume 
IM, the infectivity rate increased and the pre-patent period 
decreased: Group 1 (2,500 PfSPZ in 10 µL IM) had an infec-
tivity rate of 67% and a GM pre-patent period of 13.9 days 
(range 12.0–15.0); Group 5 (25,000 PfSPZ in 10 µL IM) had 
an infectivity rate of 100% and a GM pre-patent period of 
12.2 days (range 11.1–13.3); and Group 6 (75,000 PfSPZ in 
10 µL IM) had an infectivity rate of 100% and a GM pre-pat-
ent period of 11.4 days (range 11.0–12.0).
Additionally, the findings of the UKT trial were corrob-
orated [18]. In a different setting, with a different research 
team, lot of parasites and characteristics of volunteers, 
there were obtained almost identical results to those in 
the trial in Germany. The group (N  =  6) that received 
3,200 PfSPZ by DVI had a 100% infectivity with a GM 
pre-patent period of 11.4 days, and the group (N = 9) in 
Germany that received 3,200 PfSPZ IV had a 100% infec-
tivity rate with a GM pre-patent period of 11.2 days [18].
Volunteers injected with 3,200 PfSPZ by DVI or 75,000 
PfSPZ in 10 µL IM had infectivity rates and same GM pre-
patent periods (11.4 days) comparable to CHMI by expo-
sure to five PfSPZ-infected mosquito bites. This is the first 
clear comparison in humans between the infection rates 
after DVI and IM injection. It required 23.4-fold more 
Fig. 3 Relationship between dose of PfSPZ Challenge and pre‑patent 
period. Geometric means (horizontal bars) and 95% confidence 
intervals (vertical bars) for pre‑patent periods. Individual pre‑patent 
periods are shown.
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PfSPZ administered IM than DVI to achieve the same 
infection rate and pre-patent period. Murine studies pre-
dicted that IV/DVI would be more efficient than IM injec-
tion, but not to this degree [19]. Intradermal (ID) injection 
is not more efficient than IM, and in fact may be less effi-
cient [7, 15, 17]. It will be a significant challenge to increase 
the efficiency of IM and ID injection to make them more 
comparable to IV/DVI injection. Therefore, DVI of PfSPZ 
Challenge will be the best way, compared to the IM and 
ID inoculation, to progress CHMI studies to investigate 
anti-malarials, diagnostic tools, vaccine-induced immu-
nity targeting liver stages and erythrocytic stages, and will 
be comparable to CHMI administered by exposure to five 
PfSPZ-infected mosquito bites. It is expected that DVI with 
PfSPZ Challenge will also provide comparable results for 
vaccine-induced immunity targeting PfSPZ. However, it 
has been argued that antibodies in the skin may play a role 
in such immunity, and bypassing the skin with DVI injec-
tion of PfSPZ may underestimate the effect of such anti-
bodies [31]. This will need to be assessed in a clinical trial.
Conclusions
Administration of two different quantities of PfSPZ 
Challenge by two different routes of administration 
(3,200 PfSPZ by DVI and 75,000 PfSPZ in 10  µL by 
IM injection), were safe and comparable to mosquito-
administered CHMI. In consequence these inoculation 
regimens represent an alternative tool to mosquito-
administered CHMI for researchers worldwide, espe-
cially in malaria-endemic countries where vaccine and 
drug efficacy trials in semi-immune and immune indi-
viduals are greatly needed. Such studies in endemic 
countries will also provide a unique opportunity to 
study the impact of adaptive immunity and innate 
phenotypes (e.g., haemoglobinopathies) on infection 
rates, pre-patent periods and clinical manifestations 
of malaria in different populations with different lev-
els of P. falciparum exposure, studies that may be use-
ful for the development and fielding of future malaria 
vaccines.
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Fig. 4 Parasite kinetics measured by qPCR per group. Density units are parasites/mL; Limit of quantification of qPCR was 30 parasites per mL. Group 
1: 2,500 PfSPZ in 10 μL × 2 IM; group 2: 2,500 PfSPZ in 50 μL × 2 IM. Group 3: 2,500 PfSPZ in 250 μL × 2 IM; group 4: 3,200 PfSPZ in 500 μL × 1 DVI; 
group 5: 25,000 PfSPZ in 10 μL × 2 IM; group 6: 75,000 PfSPZ in 10 μL × 2 IM; PfSPZ Plasmodium falciparum sporozoites, IM intramuscular injection, 
DVI direct venous inoculation.
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